Artielle ImmunoTherapeutics Receives $100,000 New Round

  • Feed Type
  • Date
    9/9/2010
  • Company Name
    Artielle ImmunoTherapeutics
  • Mailing Address
    9020 SW Washington Square Road Tigard, OR 97223
  • Company Description
    Artielle ImmunoTherapeutics’ technology is focused on a new proprietary class of molecules known as Recombinant T cell receptor Ligands (RTLs) that can be tailored to treat a wide range of autoimmune diseases. Artielle has developed a lead compound for the treatment of multiple sclerosis, called RTL1000, which is in Phase 1 clinical trials and has received Orphan Drug status from the U.S. Food and Drug Administration.
  • Website
    http://www.artielle.com
  • Transaction Type
    Debt
  • Transaction Amount
    $100,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed